Last reviewed · How we verify
Low Dose Bisoprolol
Bisoprolol is a beta-1 selective adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart.
Bisoprolol is a selective beta-1 adrenergic receptor antagonist that reduces heart rate and blood pressure by blocking the effects of catecholamines on the heart. Used for Hypertension, Heart failure (systolic), Angina pectoris.
At a glance
| Generic name | Low Dose Bisoprolol |
|---|---|
| Also known as | Concor |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Beta-1 selective adrenergic antagonist (beta-blocker) |
| Target | Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Bisoprolol selectively blocks beta-1 adrenergic receptors on cardiac tissue, decreasing heart contractility and heart rate, which reduces myocardial oxygen demand and lowers blood pressure. The low-dose formulation is designed to minimize systemic beta-blockade while maintaining cardioselective effects, making it suitable for patients requiring gentler hemodynamic modulation. This mechanism makes it effective for hypertension and heart failure management with reduced risk of bronchospasm compared to non-selective beta-blockers.
Approved indications
- Hypertension
- Chronic heart failure
- Angina pectoris
- Post-myocardial infarction
Common side effects
- Fatigue
- Dizziness
- Bradycardia
- Hypotension
- Headache
- Dyspnea
- Insomnia
Key clinical trials
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy (NA)
- Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (PHASE2)
- Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing (PHASE4)
- A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low Dose Bisoprolol CI brief — competitive landscape report
- Low Dose Bisoprolol updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI